Kruegel AC
Gilgamesh Pharmaceuticals Inc., New York, NY, USA.
ArticlePsilocybin
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.
ArticlePsilocybin
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
ArticleIbogaine
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.
ArticlePsilocybin